Safety and Efficacy of DT-DEC01 Therapy in Duchenne Muscular Dystrophy Patients: A 12 - Month Follow-Up Study After Systemic Intraosseous Administration

Duchenne Muscular Dystrophy (DMD) is a progressive and fatal muscle-wasting disease with no known cure. We previously reported the preliminary safety and efficacy up to six months after the administration of DT-DEC01, a novel Dystrophin Expressing Chimeric (DEC) cell therapy created by fusion of myo...

Descripción completa

Detalles Bibliográficos
Autores principales: Siemionow, Maria, Biegański, Grzegorz, Niezgoda, Adam, Wachowiak, Jacek, Czarnota, Jarosław, Siemionow, Krzysztof, Ziemiecka, Anna, Sikorska, Maria H., Bożyk, Katarzyna, Heydemann, Ahlke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661797/
https://www.ncbi.nlm.nih.gov/pubmed/37707670
http://dx.doi.org/10.1007/s12015-023-10620-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10661797/
https://www.ncbi.nlm.nih.gov/pubmed/37707670
http://dx.doi.org/10.1007/s12015-023-10620-3

Ejemplares similares